中晚期非小细胞肺癌靶向治疗药物临床应用进展  

Progress in the clinical application of targeted therapy for intermediate and advanced non-small cell lung cancer

作　　者：李泓伯 杨莹 虞永峰 陆舜[1] LI Hongbo;YANG Ying;YU Yongfeng;LU Shun(Department of Oncology,Shanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200030,China)

机构地区：[1]上海交通大学医学院附属胸科医院肿瘤科,上海200030

出　　处：《世界临床药物》2025年第2期107-122,共16页World Clinical Drug

基　　金：国家自然科学基金资助项目(82030045、82202924)。

摘　　要：靶向药物的临床应用在近20年来革新了携带可药用基因突变非小细胞肺癌患者的治疗策略,并带来显著生存获益。近年来,靶向药物的种类及临床应用不断扩展,在晚期至局部晚期不可切除患者的治疗,以及可切除患者围手术期治疗的应用均取得突破性成果。在晚期患者中,靶向药物与化疗或双抗类药物的联合治疗方案也为一线治疗及后线治疗提供新方案。同时,抗体偶联药物在晚期患者的后线治疗中取得积极进展。文章综述了靶向药物在中晚期非小细胞肺癌临床应用的研究进展。The clinical use of targeted agents has revolutionized treatment strategies for non-small cell lung cancer(NSCLC) patients carrying targetable mutations for two decades,and has resulted in significant survival benefits.In recent years,the types and clinical use of targeted agents have expanded,with breakthroughs in the treatment of advanced to locally advanced unresectable patients and perioperative adjuvant treatment of resectable patients.In advanced patients,the combination of targeted drugs with chemotherapy or dual-antibody drugs has also provided new options for first-line and subsequent treatment.Meanwhile,antibody-drug conjugates have made positive progress in the subsequent treatment of advanced patients.This article aimed to review the research progress of targeted drugs in the clinical application of intermediate and advanced NSCLC.

关 键 词：靶向治疗 肺癌 非小细胞肺癌 

分 类 号：R979.19[医药卫生—药品] R734.2[医药卫生—药学]